ABSTRACT
Objective To detect the expression levels of anti-differentiation antagonizing noncoding RNA (DANCR) in exosomes from serum of gastric cancer patients and evaluate its clinical application.Methods The expression levels of DANCR in exosomes derived from the culture supernatants of gastric cancer cell lines and the serum samples of gastric cancer patients were detected by using realtime qRT-PCR.The correlations between DANCR levels and the clinicopathological parameters were analyzed.A receiver operating characteristic(ROC) curve was drawn to evaluate the diagnostic efficiency of DANCR.Results The expression level of DANCR in HGC-27 cell(4.43 ± 0.37) was significantly higher than that in GES-1 cells (1.01 ± 0.01) (P ＜ 0.05).The expression levels of DANCR in exosomes from the supernatants of HGC-27 cells(3.06 ±0.14) were significantly higher than that from GES-1 cells(1.01 ± 0.20) (P ＜ 0.05).The expression levels of DANCR in exosomes from the serum samples of gastric cancer patients [5.060 (1.380,22.785)] were significantly higher than that in gastric benign disease [0.535 (0.340,1.380)] (Z =-3.409,P ＜ 0.01) and healthy controls [1.200 (0.605,1.655)] (Z =-4.229,P ＜ 0.01).There was no significant difference in the expression levels of serum exosomal DANCR between gastric benign disease group and healthy control group(Z=-1.308,P ＞ 0.05).In addition,the expression levels of DANCR in gastric cancer patients were related to tumor size,TNA stage and lymph node metastasis.The area under the ROC curve of serum exosomal DANCR expression levels was 0.777 in the diagnosis of gastric cancer,the 95％ confidence interval was 0.678 to 0.876 and the cutoff value was 2.50.The sensitivity was 68.6％ and the specificity was 84.4％.Conclusion The expression level of serum exosomal DANCR may increase in gastric cancer patients and could be served as a novel marker for the diagnosis of gastric cancer.